GHRP-6 vs MK-677

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 dosage in research contexts: studies have used subcutaneous and intravenous doses typically in the range of 100–300 mcg per injection. In research protocols, GHRP-6 is often administered 2–3 times daily — before meals, before training, or before sleep — to leverage the body's natural GH pulse windows. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection following reconstitution with bacteriostatic water. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.

MK-677 mimics the action of ghrelin by binding to and activating the GHSR-1a receptor in the pituitary gland, stimulating pulsatile GH release. Its oral bioavailability distinguishes it from peptide-based GH secretagogues and its prolonged half-life results in sustained IGF-1 elevation. Research protocols have explored its effects on lean body mass, bone mineral density, and sleep architecture.

MK-677 (ibutamoren; ibutamoren mesylate) is an orally active, non-peptide small-molecule ghrelin receptor (GHS-R1a) agonist developed by Merck as a research compound for GH deficiency and muscle-wasting conditions, notable as one of the few GH secretagogues with confirmed oral bioavailability and a substantial human clinical dataset spanning multiple Phase 2 randomized controlled trials. MK-677 mimics ghrelin to stimulate pulsatile GH and IGF-1 secretion from the pituitary in a dose-dependent manner without directly replacing GH, and RCTs have demonstrated significant increases in fat-free mass and GH secretion in obese adults and in hemodialysis patients with nutritional deficits, establishing the pharmacology of oral GHS-R1a agonism in humans. Despite robust human pharmacological evidence, MK-677 was not advanced to FDA registration; Merck Phase 3 trials showed efficacy on surrogate endpoints but did not demonstrate the clinical outcomes required for approval, commercial development was discontinued, and no approved indication exists. MK-677 is a non-peptide research compound — not a peptide in the pharmacological sense — with no FDA approval; it is widely available through research chemical suppliers and used off-label, and considerations including its documented effects on insulin sensitivity, fasting glucose, and sustained IGF-1 elevation are relevant to its risk profile. MK-677 dosage: clinical trials studied doses of 10 mg, 25 mg, and 50 mg orally once daily. The most frequently cited research dose in the literature is 25 mg/day for body composition studies; 10 mg/day has been used in elderly populations. Administration before sleep is studied to align the GH pulse with the natural nocturnal GH peak. Unlike injectable GH secretagogues that require reconstitution, MK-677's oral route is a practical distinction — it eliminates the injection preparation process relevant to peptides requiring bacteriostatic water reconstitution. Side effects documented in RCTs include increased appetite (a direct ghrelin-mimetic effect), mild peripheral edema from water retention, and transient increases in fasting blood glucose — a clinically relevant finding for individuals with pre-existing insulin sensitivity concerns. Sustained IGF-1 elevation from long-duration use is a differentiated risk characteristic compared to short-half-life injectable GHRPs. MK-677 is sometimes grouped with performance peptides due to overlapping research contexts but is pharmacologically a non-peptide small molecule. Licensed telehealth and anti-aging providers who carry growth hormone secretagogues are listed in the PeptideBase directory.